226 related articles for article (PubMed ID: 32508839)
1. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Kishimoto TK
Front Immunol; 2020; 11():969. PubMed ID: 32508839
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.
Ilyinskii PO; Roy CJ; LePrevost J; Rizzo GL; Kishimoto TK
Front Immunol; 2021; 12():637469. PubMed ID: 34113339
[TBL] [Abstract][Full Text] [Related]
3. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Sands E; Kivitz A; DeHaan W; Leung SS; Johnston L; Kishimoto TK
Nat Commun; 2022 Jan; 13(1):272. PubMed ID: 35022448
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
5. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
Kishimoto TK; Ferrari JD; LaMothe RA; Kolte PN; Griset AP; O'Neil C; Chan V; Browning E; Chalishazar A; Kuhlman W; Fu FN; Viseux N; Altreuter DH; Johnston L; Maldonado RA
Nat Nanotechnol; 2016 Oct; 11(10):890-899. PubMed ID: 27479756
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).
Kivitz A; DeHaan W; Azeem R; Park J; Rhodes S; Inshaw J; Leung SS; Nicolaou S; Johnston L; Kishimoto TK; Traber PG; Sands E; Choi H
Rheumatol Ther; 2023 Aug; 10(4):825-847. PubMed ID: 37069364
[TBL] [Abstract][Full Text] [Related]
7. Encapsulating an Immunosuppressant Enhances Tolerance Induction by Siglec-Engaging Tolerogenic Liposomes.
Pang L; Macauley MS; Arlian BM; Nycholat CM; Paulson JC
Chembiochem; 2017 Jul; 18(13):1226-1233. PubMed ID: 28231415
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.
Kishimoto TK; Maldonado RA
Front Immunol; 2018; 9():230. PubMed ID: 29515571
[TBL] [Abstract][Full Text] [Related]
9. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia.
Ilyinskii PO; Michaud AM; Rizzo GL; Roy CJ; Leung SS; Elkins SL; Capela T; Chowdhury A; Li L; Chandler RJ; Manoli I; Andres-Mateos E; Johnston LPM; Vandenberghe LH; Venditti CP; Kishimoto TK
Mol Ther Methods Clin Dev; 2021 Sep; 22():279-292. PubMed ID: 34485611
[TBL] [Abstract][Full Text] [Related]
10. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
Maldonado RA; LaMothe RA; Ferrari JD; Zhang AH; Rossi RJ; Kolte PN; Griset AP; O'Neil C; Altreuter DH; Browning E; Johnston L; Farokhzad OC; Langer R; Scott DW; von Andrian UH; Kishimoto TK
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E156-65. PubMed ID: 25548186
[TBL] [Abstract][Full Text] [Related]
11. Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation.
Zhang AH; Rossi RJ; Yoon J; Wang H; Scott DW
Cell Immunol; 2016 Mar; 301():74-81. PubMed ID: 26687613
[TBL] [Abstract][Full Text] [Related]
12. Mitigation of Anti-Drug Antibody Production for Augmenting Anticancer Efficacy of Therapeutic Protein via Co-Injection of Nano-Rapamycin.
Chang Y; Xiong W; Zou C; Zeng P; Hou J; Muhitdinov B; Shen Y; Huang Y; Guo S
Small; 2024 Jan; 20(3):e2303916. PubMed ID: 37705134
[TBL] [Abstract][Full Text] [Related]
13. Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
Ilyinskii PO; Roy C; Michaud A; Rizzo G; Capela T; Leung SS; Kishimoto TK
PNAS Nexus; 2023 Nov; 2(11):pgad394. PubMed ID: 38024395
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles.
Ilyinskii PO; Michaud AM; Roy CJ; Rizzo GL; Elkins SL; Capela T; Chowdhury AC; Leung SS; Kishimoto TK
Sci Adv; 2021 Feb; 7(9):. PubMed ID: 33627416
[TBL] [Abstract][Full Text] [Related]
15. Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.
Srivastava A; Arlian BM; Pang L; Kishimoto TK; Paulson JC
ACS Chem Biol; 2021 Oct; 16(10):1985-1993. PubMed ID: 34037371
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
17. Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.
LaMothe RA; Kolte PN; Vo T; Ferrari JD; Gelsinger TC; Wong J; Chan VT; Ahmed S; Srinivasan A; Deitemeyer P; Maldonado RA; Kishimoto TK
Front Immunol; 2018; 9():281. PubMed ID: 29552007
[TBL] [Abstract][Full Text] [Related]
18. Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.
Mazor R; King EM; Onda M; Cuburu N; Addissie S; Crown D; Liu XF; Kishimoto TK; Pastan I
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E733-E742. PubMed ID: 29311317
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells.
Anderson KM; Zimring JC
Transplantation; 2006 Jan; 81(1):88-94. PubMed ID: 16421482
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model.
Glassman FY; Balu-Iyer SV
Int J Pharm; 2018 Sep; 548(1):642-648. PubMed ID: 29981412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
